I am a medical oncologist with more than 20 years of experience in treating patients with a broad spectrum of head and neck malignancies including tumors of the mouth, throat, thyroid, salivary glands, and skin. For these years of service, I was honored to receive Memorial Sloan Kettering’s Willet F. Whitmore Award for Clinical Excellence in 2011.
As Chief of the Head and Neck Oncology Service and Co-Leader of our multidisciplinary disease management team, I work closely with an esteemed and highly coordinated group of medical oncologists, surgeons, radiation oncologists, nurses, and other healthcare professionals to provide our patients with the very best care possible.
Collaborative, multidisciplinary care is especially important for cancers of the head and neck because, generally speaking, treatment not only involves a potentially deadly disease but also issues related to physical appearance, function, and quality of life. An approach that I pioneered with Memorial Sloan Kettering colleagues — known as combined modality organ preservation therapy — uses a combination of chemotherapy and radiation to avoid certain surgical procedures feared by patients such as removal of the voice box, with the intent of preserving function and cosmetic appearance without compromising survival.
My current research is focused on evaluating new forms of chemotherapy called targeted therapies, which selectively kill cancer cells while leaving healthy cells alone. I am also developing customized combined modality therapies based on prognostic risk, and assessing healthcare outcomes.
I have published extensively, previously serving as an associate editor for Clinical Cancer Research and on the editorial board of the Journal of Clinical Oncology, and have been principal investigator on multiple studies.
In addition to being a member of the board of directors for the National Comprehensive Cancer Network, I chair the organization’s head and neck cancer practice guidelines panel. I am also on the board of directors for the International Thyroid Oncology Group, and am co-chair of the Head and Neck Cancer Recurrent/Metastatic Disease Task Force at the National Cancer Institute. Here at Memorial Sloan Kettering, I chair the Committee on Metrics of Care Quality and Outcome.
- Clinical Expertise: Head and Neck Cancers (Larynx/Upper Aerodigestive, Thyroid, Salivary Gland, Skin); Lung Cancer; Genitourinary Malignancies; Larynx/Organ-Preserving Therapies; Immunotherapy; Outcomes Research
- Languages Spoken: English
- Education: MD, University of Pennsylvania School of Medicine
- Residencies: Hospital of the University of Pennsylvania
- Fellowships: Yale University School of Medicine/Yale-New Haven Hospital; Memorial Sloan Kettering Cancer Center; The New York Hospital/Cornell Medical Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by David G. Pfister
- A Phase I Study of BYL719 Given with Cetuximab and Radiation Therapy in Patients with Stage III/IVB Head and Neck Cancer
- A Phase I/II Study of BYL719 plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Cancer
- A Phase IB Study of INC280 plus Cetuximab in Patients with Recurrent or Metastatic Colorectal or Head and Neck Cancer
- A Phase II Study of Pembrolizumab in Patients with Squamous Cell Head and Neck Cancer that Has Come Back or Spread After Platinum and Cetuximab
- A Pilot Study of Ribavirin to Treat Recurrent or Metastatic HPV-Related Cancers
Clinical Trials Co-Investigated by David G. Pfister
- A Phase I Study of LY2940680 in Patients with Advanced Basal Cell Skin Cancer
- A Phase IB Study of Urelumab (BMS-663513) plus Cetuximab in Patients with Persistent Head and Neck or Colorectal Cancer
- A Phase II Study of Regorafenib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
- A Phase II Study of Sorafenib Alone and with Everolimus in Patients with Hurthle Cell Thyroid Cancer that Does Not Response to Radioactive Iodine Therapy
- A Phase II Study of Tipifarnib in Patients with Advanced Solid Tumors Containing HRAS Mutations
- A Phase II Study of Trametinib to Enhance Radioactive Iodine (RAI) Uptake in Patients with RAI-Resistant Recurrent or Metastatic Thyroid Cancer
- A Pilot Study of Vemurafenib and KTN3379 to Enhance Radioactive Iodine (RAI) Uptake in Patients with RAI-Resistant Thyroid Cancer
- A Pilot Study of Vemurafenib to Enhance Radioactive Iodine (RAI) Uptake in Patients with RAI-Resistant Thyroid Cancer
- Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus on Quality of Life